# Retatrutide: A Physician-Adjacent Reading of the Phase 1b–Phase 3 Trial Record > Retatrutide, an investigational GIP/GLP-1/glucagon triple agonist, cut body weight by up to 24.2% at 48 weeks in a Phase 2 trial [1]. A cited, plain-English reading of the trial record. A physician-adjacent reading of the published record on this investigational triple-agonist — the endpoints, the doses studied, and the questions the trials have not yet answered — with every number walked back to its source. ## The short version Retatrutide is an experimental medicine being studied for weight loss and type 2 diabetes. It is a single molecule that switches on three of the body's own hormone signals at once — GLP-1, GIP, and glucagon — which is why scientists call it a triple agonist (one key that fits three locks). In plain terms, it quiets appetite and helps the body burn more energy, and in trials people lost a large amount of weight. In one 48-week study, the highest dose led to about a 24% drop in body weight [1]. It is given as a once-a-week shot under the skin. Retatrutide is still investigational — not approved by the FDA — so everyone who has taken it did so inside a clinical trial. Side effects were mostly stomach-related, such as nausea, plus a small rise in heart rate; what people report, including the downsides, is on the page for [reported effects and safety](/effects). This site reads the trial record study by study and explains, in plain language, what each one actually measured. ## What does retatrutide do Retatrutide activates the GLP-1, GIP, and glucagon receptors with one engineered peptide [3]. The GLP-1 and GIP arms lower appetite and sharpen glucose-dependent insulin release; the glucagon arm adds energy expenditure and helps the liver mobilize fat [6]. Stacking all three signals is the design idea: earlier medicines in this class hit one or two of these receptors, and the trials to date suggest the third arm is what pushes the weight-loss numbers higher than dual- or single-receptor agents have reached [6]. A 2025 review frames the roughly 24% weight loss seen at the top Phase 2 dose over 48 weeks as a step-change over prior incretin therapies [6]. Practically, the receptors do different jobs. The GLP-1 and GIP receptors are incretin receptors — they respond to gut hormones released after eating, amplifying insulin only when blood sugar is elevated, which is why the class rarely causes lows on its own [2]. The glucagon receptor is the unusual addition: glucagon normally raises blood sugar, but at controlled agonist levels it nudges the body to spend more energy and clear fat from the liver, an effect visible in the fatty-liver substudy where liver fat fell by more than 80% [5]. The molecule itself is a 39-amino-acid peptide carrying a fatty-acid tail that keeps it circulating for about a week [4]. None of this is a treatment instruction — it is a description of what the published pharmacology and trials report about an investigational compound. ## What the trials have measured so far The trial record is unusually deep for a drug still in development. The first-in-human Phase 1b study established an elimination half-life of about six days — the pharmacokinetic basis for once-weekly dosing — and the highest-dose group lost 8.96 kg more than placebo over 12 weeks [4]. The 48-week Phase 2 obesity trial then reported a mean body-weight change of -24.2% at 12 mg once weekly versus -2.1% with placebo [1]. In type 2 diabetes, a 36-week Phase 2 trial lowered HbA1c (a three-month blood-sugar marker) by 2.02 percentage points at 24 weeks and reduced body weight by 16.94% at 36 weeks, both at 12 mg [2]. A Phase 2a substudy in fatty liver disease cut liver fat by 82.4% at 24 weeks, with 86% of participants reaching a normal liver-fat level [5]. A 2025 meta-analysis of three randomized trials (878 patients) pooled the weight effect at a mean -14.33% versus placebo [13]. The trial-by-trial breakdown lives on the page for [retatrutide results across the trials](/results), and the head-to-head framing on [retatrutide vs tirzepatide](/vs-tirzepatide). ## Where retatrutide sits among incretin therapies Retatrutide belongs to the incretin family — the same broad class as the gut-hormone-based medicines that have reshaped obesity and diabetes care over the past decade. What sets it apart is the number of receptors it engages. Single agonists act on one receptor; dual agonists act on two; retatrutide is a triple agonist, adding the glucagon receptor to the GLP-1 and GIP targets [3][8]. A 2026 review of the field describes a steadily expanding armamentarium of single, dual, and triple agonists now being tested across obesity and cardio-kidney-liver-metabolic disease, with retatrutide among the most-watched triple agents [8]. The practical significance is that each added receptor is a bet on a larger or broader effect — and, potentially, a different side-effect profile. Retatrutide's Phase 2 weight numbers are the largest reported in the class to date [1][6], but larger numbers in separate trials are not the same as proven superiority, which is why the head-to-head comparison is treated carefully on [retatrutide vs tirzepatide](/vs-tirzepatide). The honest summary: a promising design with striking early data and pivotal trials still to report [7]. ## How this reading is organized This reading is organized the way a clinician skims a file. The mechanism — the [triple-receptor mechanism of action](/research) — sits with the key studies on the research page. The efficacy readouts, endpoint by endpoint, sit on the results page. The dose ranges studied and the [half-life and pharmacokinetics](/dosage) sit on the dosage page, framed strictly as research context, never as a recommended dose. Reader questions are answered plainly in the [frequently asked questions about retatrutide](/faq), and every quantitative claim on the site traces to the [full reference list](/references). Two cautions frame everything here. First, retatrutide is investigational: as of 2026 it is in Phase 3 trials and is not approved by the FDA or any regulator, so all of the figures come from studies, not from a label [1][6]. Second, the largest numbers come from Phase 2 trials of a few hundred people; the pivotal Phase 3 program — obesity, diabetes, and dedicated cardiovascular and kidney-outcome trials — is still running and has not reported [7]. The through-line is discipline: numbers are attributed to the study that produced them, reviews and registrations are labeled as such, and the compound's unapproved status is kept in plain view rather than buried in a footnote. --- An illuminated reading of the retatrutide trial record — Phase 1b pharmacokinetics through the Phase 3 TRIUMPH program, each figure lettered back to its source, and no clinic, prescription, or apothecary behind the page.